Swedish Orphan Biovitrum AB (FRA:B6E)
€ 24.42 -0.08 (-0.33%) Market Cap: 8.36 Bil Enterprise Value: 10.02 Bil PE Ratio: 42.61 PB Ratio: 2.56 GF Score: 88/100

Swedish Orphan Biovitrum AB (publ) to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology Call Transcript

Sep 30, 2019 / 08:00AM GMT
Release Date Price: €12.83 (-9.08%)
Operator

Ladies and gentlemen, welcome to the Sobi to acquire Dova Pharmaceuticals, creating a global growth platform in hematology webcast.

I will now hand over to Guido Oelkers, CEO. Please go ahead.

Guido Oelkers;publ;CEO;President
Swedish Orphan Biovitrum AB

()-&

Yes. Good morning, and thank you. Good morning, everybody, and thanks for your early attention to our story. And what I would like to share with you today is really the source behind the Dova acquisition -- Dova Pharmaceutical acquisition and also share -- shed some light on the other announcement that we have made recently with regard to the early opt-in regarding BIVV001.

So maybe with this, let's go right into the action. I will be joined during this call by our Chief Financial Officer, Henrik Stenqvist; and our Chief Medical Officer, Milan Zdravkovic.

With this having said, so basically what is Dova and/or Doptelet? Dova is a single asset company and Doptelet being the main asset is an orally administered TPO. We think it's

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot